| 尚卿.超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间分析[J].实用中西医结合临床,2023,23(16): |
| 超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间分析 |
| Clinical Outcomes and Progression-free-survival Time of Patients with Stage Ⅲ~Ⅳ Primary Liver Cancer Receiving Ultrasound-guided Percutaneous Microwave Ablation |
| 投稿时间：2023-04-17 修订日期：2023-05-05 |
| DOI： |
| 中文关键词: 超声引导下微波介入 Ⅲ~Ⅳ期 原发性肝癌 病灶无进展 生存时长 |
| 英文关键词: Ultrasound-guided percutaneous microwave ablation Stage Ⅲ~Ⅳ Primary liver cancer Efficacy Progression-free-survival |
| 基金项目: |
|
| 摘要点击次数: 293 |
| 全文下载次数: 118 |
| 中文摘要: |
| 目的：分析超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌疗效及病灶无进展生存时间。方法：随机选择医院2020年8月-2021年8月诊治的Ⅲ~Ⅳ期PLC患者122例。据入院顺序不同分为对照组（n=60）和观察组（n=62）。对照组患者接受经肝动脉的化疗栓塞相关治疗，观察组病人实施超声引导情况下的微波介入治疗。比较两组患者血清肿瘤标志物水平、临床疗效、病灶无进展生存时间和生活质量、并发症和不良反应。结果：治疗后，两组患者AFP和CEA水平较治疗前下降，且观察组患者AFP（4.06±1.03）和CEA（4.06±0.38）水平低于对照组（P<0.05）。两组患者治疗后的AST、ALT、GGT、ALP和TBIL均低于治疗前，DBIL高于治疗前，差异均具有统计学意义（P＜0.05），但两组治疗后数据对比，差异不具有统计学意义（P＞0.05）。VAS评分方面，两组病人治疗后较治疗前下降，且观察组病人治疗后（1.87±0.30）分较对照组（2.85±0.35）分病人低（P<0.05）。观察组患者完全缓解率高于对照组（P<0.05），局部残留率和转移复发率低于对照组（P<0.05）。观察组患者病灶无进展生存时间（10.49±0.34）长于对照组（P<0.05）。生活质量评分这一方面，较治疗前治疗后两组病人上升，且观察组病人生活质量方面的评分（79.58±3.02）较对照组高（P<0.05）。观察组患者并发症率低于对照组（P<0.05）。不良反应出现概率方面，观察组患者率低于病人较对照组病人低（P<0.05）。结论：超声引导下微波介入治疗Ⅲ~Ⅳ期原发性肝癌能明显提升疗效，延长病灶无进展生存的具体时长，改善其日常的生活质量，建议使用。 |
| 英文摘要: |
| Objective To investigate the clinical outcomes and progression-free-survival time of patients with stage Ⅲ~Ⅳ primary liver cancer (PLC) receiving ultrasound-guided percutaneous microwave ablation. Methods A total of 122 patients with PLC in our hospital from August 2020 to August 2021 were enrolled, and divided into 2 groups according to dmission order. Control group (n=60) received transhepatic arterial chemotherapeutic embolism (TACE), while observation group (n=62) received ultrasound-guided percutaneous microwave ablation, then the serum tumor marker levels, clinical eff icacy, progression-free survival time, quality of life, complications and adverse reactions were compared between groups. Results Levels of alpha fetoprotein (AFP) and carcino-embryonic antigen (CEA) were decreased in both groups after treatment, and the levels were (4.06±1.03) and (4.06±0.38) in observation group, which were obvious lower than control group, with statistical difference (P<0.05). The AST,ALT,GGT,ALP,and TBIL of the two groups of patients after treatment were lower than before treatment,while DBIL was higher than before treatment,with statistical significance(P<0.05).However,the difference in data between the two groups after treatment was not statistically significant(P>0.05).In terms of VAS score,the two groups of patients showed a decrease after treatment compared to before treatment,and the observation group had a lower score after treatment(1.87±0.30)compared to the control group(2.85±0.35)(P<0.05).Compared with control group, observation group had higher complete remission rate, as well as lower local residual rate and metastasis recurrence rate (P<0.05). The progression-free-survival time was (10.49±0.34) in observation group, which was obvious longer than control group (P<0.05). There was an increase in the quality of life score in 2 groups after treatment, and the score was (79.58±3.02) in observation group, which was obvious higher than that of control group (P<0.05). Observation group had lower complication rate and adverse reaction rate than control group, with statistical difference (all P<0.05). Conclusion Ultrasound-guided percutaneous microwave ablation in the treatment of stage Ⅲ~Ⅳ primary liver cancer can effectively prolong the survival time and improve the quality of life, which is worthy of recommendation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
